SL-66. Inhibitors of microRNA-21

ASINEX
Signature Libraries

Aberrant expression of microRNA-21 (miR-21) has been observed in many different types of cancer such as glioblastoma, lymphoma, breast, pancreatic, cervical, colorectal, ovarian, etc in addition to being associated with autoimmune and neurological responses [1].

Small molecules that can bind directly to miR-21 have been suggested as a promising new therapy for the treatment of cancer [2]. Screening a large library of druglike small molecules has identified several chemotypes that bind to the pre-miR-21 hairpin with high selectivity against other oligonucleotides. The most potent hit molecules share the common 1-amino-3-(9H-carbazol-9-yl)propan-2-ol scaffold which can be considered a privileged fragment.

80 molecules containing this privileged fragment were included in this library.



LAS 00340464



LAS 00340482



LAS 52133541



Preferrred Scaffold for miR-21 binding[2]

Signature Library 66

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 µmol; 1 µmolDMSO solutions	SL#66_miR-21.sdf

References:

1. *Biomed Rep. 2016 Oct; 5(4): 395–402. doi: 10.3892/br.2016.747*
2. *ACS Chemical Biology.* (2016). doi:1021/acschembio.6b00945.

Contact us:

USA:	+1 336 721 1617	mparisi@asinex.com
Japan:	+81-80-3401-9097	sota@asinex.com
Europe/Global:		lsadovenko@asinex.com